Stockwinners Market Radar for December 15, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:44 EST Arhaus CFO buys 50,000 class A shares - In a regulatory filing, Arhaus CFO Dawn Phillipson disclosed the purchase of 50,000 class A common shares of the company on December 14 at a price of $11.62 per share.

19:42 EST Realty Income raises monthly divided to 24.65c per share from 24.6c - Realty Income Corporation announced its Board of Directors has declared an increase in the company's common stock monthly cash dividend to 24.65c per share from 24.6c per share. The dividend is payable on January 14, 2022 to shareholders of record as of January 3, 2022. This is the 114th dividend increase since Realty Income's listing on the NYSE in 1994. The ex-dividend date for January's dividend is December 31, 2021. The new monthly dividend represents an annualized dividend amount of $2.958 per share as compared to the current annualized dividend amount of $2.952 per share.

19:11 EST Mesoblast receives feedback from FDA's OTAT on rexlemestrocel-L program - Mesoblast announced that it has received feedback from the US Food & Drug Administration's Office of Tissues and Advanced Therapies on the Phase 3 program of rexlemestrocel-L in patients with chronic low back pain due to degenerative disc disease refractory to available therapies, including opioids. Mesoblast plans to conduct an additional US Phase 3 trial which may support submissions for potential approval in both the US and EU. The trial will include at least 20% of subjects from the EU to support global submission plans. Following review of the completed Phase 3 trial data, OTAT agreed with Mesoblast's proposal for pain reduction at 12 months as the primary endpoint of the next trial, with functional improvement and reduction in opioid use as secondary endpoints. If this trial is successful and leads to EU regulatory approval, Mesoblast will be eligible to receive payments up to $112.5M prior to product launch in the EU, from its partner in Europe and Latin America, Grunenthal, inclusive of $17.5M already received, if certain clinical and regulatory milestones are satisfied and reimbursement targets are achieved. Cumulative milestone payments could reach $1B depending on the final outcome of Phase 3 studies and patient adoption. Mesoblast will also receive tiered double-digit royalties on product sales.

19:02 EST Chesapeake Utilities acquires propane operating assets of Diversified Energy - Chesapeake Utilities Corporation announced that its propane subsidiary, Sharp Energy, has acquired the propane operating assets of Diversified Energy Company. Through this acquisition, the company expands its operating footprint into North Carolina and South Carolina. "Sharp Energy has driven significant growth for Chesapeake Utilities as a market leader in residential, commercial, wholesale and AutoGas propane services. Propane remains a core part of our unregulated energy operations given its high demand, especially in more rural areas where natural gas pipelines cannot or have not yet reached," said Jeff Householder, president and chief executive officer, Chesapeake Utilities. "The addition of Diversified Energy's propane business expands Sharp's footprint into the Carolinas, adding to our growing presence along the East Coast. We are pleased to welcome our new employees to the Chesapeake Utilities family and are committed to serving Sharp's new customers with a continued commitment to excellence, integrity and care." "We believe the two organizations align culturally, and we are excited to integrate the Diversified Energy business into Sharp Energy," said Andy Hesson, vice president of Sharp Energy. "With this transaction, our propane business will add approximately 19,000 residential, commercial and agricultural customers, along with distribution of approximately 10 million gallons of propane annually." The deal is expected to be accretive to Chesapeake Utilities' 2022 earnings, adding approximately $11.3M in gross margin for 2022.

18:57 EST Sangoma announces listing of common shares on Nasdaq - Sangoma Technologies Corporation announced that it expects its Common Shares to be listed on the Nasdaq Global Select Market commencing tomorrow, Thursday December 16, 2021. The company's common shares will continue to trade on the Toronto Stock Exchange under the symbol "STC" and will now trade on NASDAQ under the trading symbol 'SANG."

18:06 EST Verrica Pharmaceuticals says FDA accepts NDA resubmission for VP-102 - Verrica Pharmaceuticals announced that the U.S. Food and Drug Administration acknowledged that Verrica's resubmitted New Drug Application for VP-102 for the treatment of molluscum contagiosum was complete and assigned a Prescription Drug User Fee Act goal date of May 24, 2022. "We are pleased that the FDA has accepted our NDA resubmission for VP-102," said Ted White, Verrica's President and Chief Executive Officer. "While we recognize the demands of the Agency's current workload, we intend to work with the FDA toward approval as quickly as possible based on the limited changes in our resubmission. We continue to be encouraged by the overwhelming demand from both caregivers and the medical community for an FDA-approved treatment for molluscum, one of the largest unmet needs in medical dermatology."

18:01 EST Plug Power, Edison Motors partner on hydrogen-powered city buses - Edison Motors, a Korean electric car manufacturer, announced that the company signed an agreement with NY-based Plug Power to develop and bring to market a hydrogen fuel cell-powered electric city bus. Plug Power's 125kW ProGen fuel cell engine will provide power to Edison Motors' electric bus platform. The companies expect to have a fuel cell electric bus prototype completed by the second half of 2022 and be prepared to launch a mass-market platform by the first half of 2023.

17:40 EST Assertio Holdings acquires Otrexup from Antares Pharma for $44M - Assertio Holdings (ASRT) has acquired Otrexup - methotrexate -, a drug device combination single dose once weekly auto-injector, from Antares Pharma (ATRS) in the company's first new product acquisition since 2015. The acquisition was made through a subsidiary. Assertio acquired Otrexup from Antares in a partially seller financed transaction for a total purchase price of $44.0M inclusive of working capital investments. Payment terms are as follows: $18.0M in cash on December 15, 2021; $16.0M in cash on May 31, 2022; and $10.0M in cash on December 15, 2022. Otrexup is a once weekly single dose auto-injector containing a prescription medicine, methotrexate, which is indicated for severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis, and to control the symptoms of severe, resistant, disabling psoriasis in adults when other types of treatment have been used and did not work well.

17:13 EST FDA grants Calliditas approval for Tarpeyo to reduce proteinuria from IgAN - Calliditas Therapeutics announced that the US Food and Drug Administration, FDA, has approved TARPEYO, budesonide, delayed release capsules to reduce proteinuria in adults with primary immunoglobulin A nephropathy , IgAN, at risk of rapid disease progression, generally a urine protein-to-creatinine ratio, UPCR, greater than or equal to1.5g/g. This indication is approved under accelerated approval. It has not been established whether TARPEYO slows kidney function decline in patients with IgAN. Continued approval may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial.1 This approval marks the successful transition for Calliditas to a commercial-stage biopharmaceutical company. "We are very excited to bring the first and only FDA-approved treatment to reduce proteinuria in IgAN to market," said Renee Aguiar-Lucander, Chief Executive Officer of Calliditas. "TARPEYO represents an FDA approved product to help these patients who are at risk of rapid disease progression." TARPEYO is approved under accelerated approval based on achieving its primary endpoint of reduction in proteinuria in Part A of the NeflgArd pivotal Phase 3 study, an ongoing, randomized, double-blind, placebo-controlled, multicenter study conducted to evaluate the efficacy and safety of TARPEYO 16 mg once daily vs placebo in adult patients with primary IgAN.1 The effect of TARPEYO was assessed in patients with biopsy-proven IgAN, eGFR greater than or equal to35 mL/min/1.73 m2, and proteinuria .

17:11 EST Blue Apron launching co-branded credit card with Aspiration - Blue Apron announced plans for a Blue Apron Aspiration Zero Card, a co-branded credit card created in collaboration with Aspiration, which offers its cardholders rewards to help fight the climate crisis. The Blue Apron Aspiration Zero Card will reward cardmembers on qualifying purchases made at BlueApron.com and on the Blue Apron mobile app, as well as extend benefits currently available to all Aspiration Zero Card customers. By using the Blue Apron Aspiration Zero Card, customers will be able to offset a part of their carbon footprint. With every qualifying purchase made on a Blue Apron Aspiration Zero Card, Aspiration will plant a tree and let users plant an additional tree by rounding up purchases to the nearest dollar. In addition to providing credit card services, Aspiration intends to commit to promote Blue Apron to its customers. Blue Apron expects to launch other new programs in 2022.

17:02 EST eBay changes definition of GMV, no material change to guidance - eBay announced it has changed its definition of Gross Merchandise Volume, or GMV, to align with customer money flows on its platforms. GMV provides a useful measure of the overall transaction volume on eBay's platforms and is correlated to net transaction revenue. The company has updated its definition of GMV to include all paid transactions on its platforms inclusive of shipping fees and taxes. Previously, eBay reported GMV regardless of whether the buyer and seller actually consummated the transaction. This change has been enabled by the increased visibility derived from the company's transition to managing payments globally. The updated GMV definition has an immaterial impact on previously reported GMV. GMV under this new definition does not materially change guidance issued by the company on October 27.

16:48 EST Retail Value declares special common share distribution of$3.27 per share - Retail Value declared a special cash distribution on its Common Shares of $3.27 per common share payable on January 18, 2022 to shareholders of record at the close of business on December 29, 2021. The special cash distribution is expected to be return of capital which would reduce the shareholder's tax basis in its shares.

16:46 EST Indus Realty Trust raises quarterly dividend 6.7% to 16c per share - The dividend will be payable on January 14, 2022, to stockholders of record on December 30, 2021.

16:40 EST Canoo, VDL Groep to explore opportunities to partner together - Canoo and VDL Groep announced that the two companies are exploring opportunities to partner together. The companies have ceased contract manufacturing discussions, which will facilitate Canoo's ability to utilize the incentives from Oklahoma and Arkansas. In addition, VDL Nedcar will return Canoo's prepayment of $30.4M. To underline the new relationship VDL Groep will also purchase $8.4M of Canoo stock.

16:37 EST Lennar sees FY22 gross margin 27%-27.5% - Stuart Miller, Executive Chairman of Lennar, said, "The housing industry continues to exhibit strong demand, outweighing supply, and we are confident that we will continue to generate solid growth and enhance our current market position. Accordingly, as we look forward to 2022, we expect to deliver approximately 67,000 homes with a 27.0% - 27.5% gross margin for the year, with more or less 12,500 homes at a gross margin of approximately 26.75% in the first quarter. Overall, we are operating from a position of strength with an excellent balance sheet enabling us to continue to execute on our core strategies."

16:36 EST Lennar reports Q4 deliveries of 17,819 homes, up 11% - New orders increased 2% to 15,539 homes; new orders dollar value increased 16% to $7.3B. Backlog increased 26% to 23,771 homes; backlog dollar value increased 45% to $11.4B.

16:34 EST BayCom board approves 747K share stock repurchase pact 'over a one year period' - BayCom announced that its Board of Directors approved a stock repurchase program for the repurchase of up to 747,000 shares of its common stock, or approximately 7% of its outstanding shares, over a one year period through open market purchases, privately-negotiated transactions, or otherwise in compliance with Rule 10b-18 under the Securities Exchange Act of 1934. "We are pleased to announce our fifth stock repurchase program which reflects our commitment to manage our capital prudently and in a manner which we believe will enhance shareholder value," said George Guarini, President and Chief Executive Officer. Mr. Guarini went on to say, "Implementing this additional stock repurchase program continues to be one of the strategies the Board believes is integral to the effective management of our capital."

16:34 EST Lennar sees FY22 deliveries 67,000 - Sees FY22 average sale price about $460,000.

16:33 EST Synchrony announces $1B boost in share repurchase authority - Synchrony Financial announced that its Board of Directors has increased the company's share repurchase authorization by $1B. The company had $1.2B remaining under its prior authorization as of September 30, 2021, so this increase will bring the amount available to $2.2B through the period ending June 30, 2022. The authorizations permit the company to repurchase shares from time to time subject to market conditions and other factors, including legal and regulatory restrictions and required approvals.

16:33 EST Color Star Technology CEO Basil Wilson resigns, Lucas Capetian succeeds - Color Star Technology announced that Basil Wilson, the company's chairman and CEO, has resigned from both positions due to health reasons. Lucas Capetian will become Color Star's new chairman and CEO. Lucas Capetian will assume the positions of chairman and CEO and lead Color Star in more rapid development of core technologies, such as its metaverse and non-fungible token products. The company said, "Upon his appointment, Sir Lucas Capetian will first increase R&D efforts for the development of metaverse products and smart-wear technologies. In the meantime, the Color Star app metaverse entertainment interface will be launched later this month. The platform will continuously incorporate and integrate the Company's entertainment technology concepts and developments to create a global celebrity interactive metaverse world."

16:20 EST Calliditas Therapeutics AB (ADS) trading resumes

16:15 EST Avanos announces $30M share repurchase program - Avanos Medical announced that its Board of Directors has approved a share repurchase program authorizing Avanos to purchase up to $30M of the company's common stock. The company expects to fund repurchases under this program from the company's existing cash or future cash flow.

16:12 EST Vishay to acquire Barry Industries for $21M - Vishay announced that it has signed a definitive purchase agreement to acquire substantially all of the assets and certain liabilities of Barry Industries for $21M, subject to working capital and net cash adjustments at closing. The all-cash transaction is expected to close on December 31, subject to the satisfaction of customary closing conditions. Based in Attleboro, Massachusetts, privately-held Barry Industries is a vertically integrated manufacturer of semiconductor packaging and resistive components including terminations, resistors and attenuators. An ISO9001 certified, ITAR registered company, Barry Industries is an approved supplier to manufacturers of military, commercial, aerospace, medical and fiber-optic devices.

16:11 EST Ensysce Biosciences enrolls first patient in PF614-MPAR study - Ensysce Biosciences announced that the first patients have been enrolled in the Phase 1 study of PF614-MPAR, the first product utilizing the company's MPAR platform designed to reduce opioid overdose.

16:09 EST Bowman Consulting acquires Kibart, terms not disclosed - Bowman Consulting Group announced the acquisition of the assets of Kibart. Established in 1986 and based in Towson, Maryland, Kibart delivers a variety of services including mechanical, electrical and energy engineering, master planning, utility and infrastructure design, commissioning, LEED-certification design, and construction administration. Under the leadership of Ed Abbott, Kibart services its clients with a team of 35+ employees including professional engineers, LEED accredited and certified commissioning professionals, and CSI certified document technicians. "Kibart is a great addition to our growing portfolio of building services," said Gary Bowman, CEO of Bowman. "Ed and his team have designed many award-winning projects that demonstrate market leadership and innovation. The addition of Kibart builds on our acquisitions of KTA Group and PCD earlier this year and accelerates our strategy of developing a building services practice that has a national reach. In keeping with our revenue-focused approach to acquisitions, Kibart as a part of Bowman provides immediate opportunity for the cross-selling of our services and revenue growth. We are extremely pleased with the breadth of leadership we are adding and welcome everyone from Kibart to Bowman." The acquisition, which the Company expects to be immediately accretive, was financed with a combination of cash, seller financing, and stock. The Company expects the Kibart acquisition to initially contribute approximately $6.3 million of annualized net service billing.

16:08 EST Equinix collaborates with Nasdaq to scale digital infrastructure - Equinix (EQIX) announced a multi-year partnership with Nasdaq (NDAQ) to scale the Equinix NY11 data center in Carteret, New Jersey to support the build out of Nasdaq's cloud infrastructure. For more than 13 years, Nasdaq has leveraged Platform Equinix to support its extensive customer and vendor ecosystem across the world. Nasdaq's current and planned future deployments across Equinix International Business Exchange data centers include Canada, the U.S., Europe, and Asia-Pacific, with additional expansions anticipated over the next several years.

16:06 EST NuScale names James Hackett non-executive chairman - NuScale, which has agreed to go public via a merger with Spring Valley Acquisition Corp., announced that James T. Hackett will become the non-executive Chairman of the Board of Managers for NuScale Power, LLC. Hackett has served on the board of NuScale since November 2021 and as a Director on Fluor Corporation's Board of Directors since 2016. "To change the power that changes the world, NuScale needs experienced, dedicated leaders to help ensure the benefits of our small modular reactors reach every community," said John Hopkins, President and Chief Executive Officer of NuScale Power. "Jim will be an invaluable asset to the company, and we will undoubtedly benefit from his expertise and counsel as we approach and achieve commercialization."

16:03 EST Navidea completes full enrollment in Phase 2b NAV3-35 clinical study - Navidea Biopharmaceuticals announced that it has achieved full enrollment in its NAV3-35 Phase 2b clinical study titled "Development of a Normative Database for Rheumatoid Arthritis Imaging with Tc99m Tilmanocept." Establishing a healthy subject database is necessary to create a quantitative method for determining RA-involved inflammation in joints. The NAV3-35 Phase 2b clinical trial accomplishes this goal. The trial has two arms, with Arm 1 designed to acquire hand and wrist planar (two-dimensional) images from healthy subjects that were age and sex-matched to the RA population and injected with Tc99m tilmanocept. Arm 2 is a pilot feasibility study to examine the potential of three-dimensional SPECT/CT imaging of the hands and wrists of healthy subjects and patients with RA injected with Tc99m tilmanocept. The main objective of the trial is to complete the healthy subject database in support of the Company's RA imaging commercial product development. A total of 120 healthy volunteers were enrolled in Arm 1. Enrollment is also finalized in Arm 2 of the study. Tc99m tilmanocept attaches to mannose receptors on macrophages that are frequently involved in RA joint inflammation. Relatively smaller numbers of CD206-expressing macrophages normally reside in the joints of healthy people without RA. An integral part of the ability to quantitatively discriminate RA-inflamed joints from those that do not have inflammation using Tc99m tilmanocept imaging is the knowledge of the distribution of Tc99m tilmanocept localization in healthy joints. The establishment of this database will enable improved accuracy of discrimination of RA-involved joints from non-RA inflamed joints and should have a positive impact on the ability to predict treatment response early, the primary indication the Company is pursuing in RA in the upcoming Phase 3 trial. This database will also be used in the training of automated image analysis software to further improve the accuracy of the quantification of Tc99m tilmanocept localization in joints as well as the workflow for later commercialization in RA.

15:59 EST Calliditas announces FDA grants accelerated approval of Tarpeyo - Calliditas Therapeutics AB announced that the U.S. Food and Drug Administration has approved Tarpeyo, or budesonide, delayed release capsules to reduce proteinuria in adults with primary immunoglobulin A nephropathy, or IgAN, at risk of rapid disease progression, generally a urine protein-to-creatinine ratio greater than or equal to1.5g/g. "This indication is approved under accelerated approval. It has not been established whether Tarpeyo slows kidney function decline in patients with IgAN. Continued approval may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial. This approval marks the successful transition for Calliditas to a commercial-stage biopharmaceutical company," the company stated. It is expected that Tarpeyo will be available in the U.S. early in the first quarter of 2022. Reference Link

15:32 EST Donerail intends to submit revised LOI to acquire Turtle Beach - The Donerail Group, which identifies itself as "one of the largest shareholders of Turtle Beach Corporation with beneficial ownership of approximately 7.4% of the company's outstanding shares," released a statement that reads in part: "We believe that public disclosure of a Strategic Review process, while potentially disadvantageous to our efforts of acquiring the Company, would create appropriate accountability for this Board and do well to provide shareholders with a full and transparent understanding as to the actions that this Board is undertaking to create shareholder value. As a sign of our commitment to join an auction process for the Company, Donerail is declaring its intent to enter into a customary non-disclosure agreement in conjunction with a publicly disclosed Strategic Review process, and we will also agree to a customary standstill that would provide the Company with surety of our standing as a willing acquiror while simultaneously protecting our rights as shareholders to nominate directors at next year's Annual Meeting, should the need arise."

15:15 EST Bristol-Myers confirms FDA approves Orencia combo for prevention of aGvHD - Bristol Myers Squibb announced that Orencia was approved by the U.S. Food and Drug Administration for the prophylaxis, or prevention, of acute graft versus host disease, or aGvHD, in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation from a matched or 1 allele-mismatched unrelated donor. "Orencia is the first FDA-approved therapy to prevent acute graft versus host disease following hematopoietic stem cell transplant, a potentially life-threatening complication that can pose a comparatively higher risk to racial and ethnic minority populations in the U.S. due to difficulty finding appropriately matched donors. With this fourth indication for Orencia, Bristol Myers Squibb draws on its legacy and expertise in both immunology and hematology to deliver an important treatment option for patients in a disease with high unmet need," said Tina Deignan, senior vice president, U.S. Immunology, Bristol Myers Squibb. The FDA's review was conducted under its Project Orbis initiative, which enabled concurrent and/or shared FDA review with the health authorities in Canada, Switzerland and as a pilot in Israel. Orencia is not approved for this indication in these countries.

15:08 EST Calliditas Therapeutics AB (ADS) trading halted, news pending

15:01 EST Regional Health Properties Inc trading halted, volatility trading pause

14:48 EST Blue Apron trading resumes

14:42 EST Blue Apron trading halted, volatility trading pause

14:19 EST PNC Financial EVP Lyons sells 5,000 common shares - In a regulatory filing, PNC Financial executive VP Michael Lyons disclosed the sale of 5,000 common shares of the company on December 14 at a price of $198.605 per share.

14:14 EST Vaccitech PLC (ADS) trading halted, volatility trading pause

13:53 EST North American rail traffic dropped 7.5% in week ended December 11 - The Association of American Railroads or AAR, reported U.S. rail traffic for the week ending December 11. For this week, total U.S. weekly rail traffic was 513,366 carloads and intermodal units, down 6% compared with the same week last year. Total carloads for the week ending December 11 were 239,029 carloads, up 0.3% compared with the same week in 2020, while U.S. weekly intermodal volume was 274,337 containers and trailers, down 10.9% compared to 2020. North American rail volume for the week ending December 11 on 12 reporting U.S., Canadian and Mexican railroads totaled 331,925 carloads, down 3.7% compared with the same week last year, and 354,599 intermodal units, down 10.8% compared with last year. Total combined weekly rail traffic in North America was 686,524 carloads and intermodal units, down 7.5%. North American rail volume for the first 49 weeks of 2021 was 33,799,003 carloads and intermodal units, up 5% compared with 2020. Publicly traded companies in the space include CSX (CSX), Canadian National (CNI), Canadian Pacific (CP), Kansas City Southern (KSU), Norfolk Southern (NSC), Union Pacific (UNP), FreightCar America (RAIL), Trinity Industries (TRN), Greenbrier (GBX), and Wabtec (WAB). Reference Link

12:51 EST American Express reports November write-off rate 0.5% vs. 0.6% last month - Reports November 30 days past due loans as a percent of total 0.7% vs. 0.7% last month.

12:08 EST Moderna says booster 'significantly increased' titers against omicron - Moderna said via Twiiter: "First look at the assessment of our COVID-19 vaccine & 50 microgram booster against #Omicron. After the 2-dose primary series of our vaccine, while individuals had detectable neutralizing titers against Omicron, neutralizing titers were significantly lower compared to the wild-type virus. However, a #booster dose of mRNA-1273 at the 50 microgram dose level significantly increased neutralizing #antibody titers against #Omicron. These and additional data have been submitted to a preprint server. These are encouraging initial data and we are actively working on our three-part strategy to address the #Omicron variant. We expect data on 100 microgram dose booster and on our #mRNA multi-valent vaccine approaches in the coming week." Reference Link

12:03 EST Chevron Technology Ventures president Barbara Burger to retire - Chevron Corporation announced that Barbara Burger, vice president of innovation and president of Chevron Technology Ventures, will retire from the company after 34 years of service. Jim Gable, currently vice president of Downstream Technology & Services, will succeed Burger, effective February 1, 2022.

12:00 EST Ambrx Biopharma falls -11.9% - Ambrx Biopharma is down -11.9%, or -$1.17 to $8.64.

12:00 EST Rev Group falls -23.7% - Rev Group is down -23.7%, or -$3.78 to $12.15.

12:00 EST MiX Telematics rises 9.5% - MiX Telematics is up 9.5%, or $1.03 to $11.83.

11:48 EST Bristol-Myers acute graft versus host disease drug gets FDA approval - The Food and Drug Administration said approved Orencia for the prophylaxis of acute graft versus host disease. Orencia may be used in adults and pediatric patients two years of age or older undergoing hematopoietic stem cell transplantation from an unrelated donor, the agency said in a statement. This is the first FDA drug approval for acute graft versus host disease prevention. The FDA granted approval of Orencia to Bristol-Myers. Reference Link

11:43 EST Delek US, Delek Logistics announce 2022 capital spending budget $250M-$260M - Delek US Holdings (DK) and Delek Logistics Partners (DKL) announced their 2022 capital spending budget with a range of approximately $250M to $260M on a consolidated basis. Approximately $59M of the growth capital resides at Delek Logistics Partners, which is expected to be self-funding. The company said, "2022 growth is largely focused on the expansion of the Delek Permian Gathering business where demand from producers is strong. We expect to achieve well above our internal 15% target rate of return threshold for midstream growth investments. Additionally, we are expanding our growth initiatives in the retail segment with four new to industry locations now planned in 2022. Separately, we elected to conduct minor maintenance activities at Tyler in the fourth quarter of 2021, thereby allowing us to defer the start of the next turnaround until 2023. As a result, our refining throughput guidance for the fourth quarter will now be in the range of 275 to 280mbbl/d."

11:20 EST Block CFO Ahuja to join Airbnb board of directors - Airbnb (ABNB) has announced that Amrita Ahuja is joining the company's board of directors, effective immediately, and she will serve as a member of the board's audit committee. Amrita currently serves as the Chief Financial Officer at Block (SQ), formerly known as Square, and is a graduate of Harvard Business School and Duke University, Airbnb noted.

11:03 EST HTLF announces Food & Agribusiness division - HTLF announces the launch of its new Food & Agribusiness division, which offers a full suite of banking services and solutions dedicated to meeting the needs of businesses across the entire food supply chain. HTLF Food & Agribusiness is led by Hakan Erdinc, EVP, Senior Managing Director, and a hand-picked, dedicated team of senior bankers with deep roots and expertise in the industry. Their knowledge of the cyclical and seasonal nature of the business and the interconnectedness of the network of growers, producers, processors and distributors is critical to successfully partnering with food and agribusiness companies today.

10:29 EST Insignia Systems trading resumes

10:24 EST Insignia Systems trading halted, volatility trading pause

10:02 EST BAE Systems receives $493M contract modification from Lockheed Martin - BAE Systems (BAESY) received a $493 million contract modification from Lockheed Martin (LMT) to significantly upgrade and modernize the electronic warfare system for the F-35 Lightning II, enabling the fifth-generation fighter to quickly detect and address evolving electromagnetic threats in contested battlespaces.

10:00 EST MediaAlpha falls -10.4% - MediaAlpha is down -10.4%, or -$1.56 to $13.46.

10:00 EST Rev Group falls -16.8% - Rev Group is down -16.8%, or -$2.67 to $13.26.

10:00 EST CNFinance rises 6.5% - CNFinance is up 6.5%, or 30c to $4.90.

09:55 EST Nxt-ID awarded U.S. GSA contract for personal emergency response systems - NXT-ID announces it has been awarded a U.S. General Services Administration contract to bring its personal emergency response systems to federal, state and local government purchasers as of Q3 2021. NXT-ID will now be able to distribute their technology directly to long-term partners like the Veterans Health Administration and to other government agencies to help more people feel safe and secure at an affordable price.

09:47 EST Eletrobras falls -9.0% - Eletrobras is down -9.0%, or -55c to $5.53.

09:47 EST CNFinance rises 6.5% - CNFinance is up 6.5%, or 30c to $4.90.

09:47 EST Perimeter Solutions rises 21.6% - Perimeter Solutions is up 21.6%, or $2.63 to $14.81.

09:44 EST Magellan Midstream extends open season for Kansas-to-Colorado pipeline expansion - Magellan Midstream Partners announced the extension of its open season to solicit customer commitments for the potential expansion of the partnership's refined petroleum products pipeline system from Kansas to Colorado. Significant interest has been expressed from potential shippers, and the extension provides interested customers additional time to finalize commitments, the company said in a statement. Binding commitments are now due by 5:00 p.m. Central Time on Dec. 22. The approximately 450-mile pipeline currently transports various grades of gasoline, diesel fuel and jet fuel from El Dorado, Kansas to Denver, Colorado.

09:36 EST Medtronic, Virtua Health enter collaboration to improve health outcomes - Virtua Health and Medtronic announce a five-year partnership focused on improving delivery of quality care for residents of South Jersey, particularly those who reside in underserved communities or face systemic barriers to care. Medtronic LABS, an independent impact-focused organization funded by Medtronic plc, will simultaneously launch a separate pilot collaboration with the Cherry Hill Free Clinic and Virtua to address care and food access for people with chronic conditions - the first U.S.-based initiative for Medtronic LABS. The scope of the partnership includes the following projects and will expand over time. Heart Health: Medtronic plc and Virtua Health will develop a program to optimize care for hospital patients diagnosed with heart failure, with a focus on slowing the progression of the disease and enhancing the experience of both patient and provider. By employing Medtronic's data-driven, decision-support tools, Virtua clinicians will provide ongoing resources post-hospitalization, minimizing the likelihood of readmission and creating sustainable, enriching solutions for the individual. Outpatient Care Continuity: The partnership will also optimize patient care in high-value outpatient settings, including ambulatory surgery centers. Additionally, Medtronic plc and Virtua will expand Virtua's hospital at home program, which is due to launch officially in early 2022 and aims to reduce the resource-strain on the health system while allowing eligible patients to heal from the comfort of home. Medtronic LABS' collaboration intends to address population health in the following ways: Community Health and the Cherry Hill Free Clinic: Community health workers and clinicians at the Cherry Hill Free Clinic will utilize Medtronic LABS' digital health platform, extending their reach through mobile tools and point-of-care diagnostics. Those identified as having chronic illnesses, such as Type 2 diabetes or hypertension, will then connect to the Cherry Hill Free Clinic for follow-up care. Over time, the platform will become more sophisticated and specific as the data accumulates and reveals localized trends and challenges. Food Access: Medtronic LABS will also support Virtua's Eat Well food access programs, specifically the Food Farmacies located inside Virtua Mount Holly Hospital and the Virtua Health & Wellness Center - Camden. Medtronic LABS and Virtua will identify those at risk for food insecurity - due to financial circumstances or limited health literacy - and connect them to free food, nutrition education, and social-work services.

09:26 EST AYRO announces results of annual meeting, provides business update - AYRO announces results from its Annual Meeting of Stockholders held on December 14, 2021. Seven directors were elected to serve a one-year term on the Board. The appointment of Friedman LLP as AYRO's independent registered public accounting firm for the fiscal year ending December 31, 2021 was ratified. Additionally, CEO Thomas Wittenschlaeger provided a business update to shareholders. Here is a summary of discussion topics covered in the business update: Record revenue, driven by record unit shipments, is expected for the fourth quarter of 2021. Since being named CEO in late September 2021, Mr. Wittenschlaeger has led an evaluation of all aspects of AYRO's business at every level, examining both revenue and expenses, existing and potential partnerships, and overall strategy from a product portfolio standpoint. Due to supply chain disruptions and escalating shipping costs, AYRO expects to undergo a process of on-shoring the sourcing of components for the Club Car Current, its low-speed electric vehicle, from Asia to North America. A process of evaluating and clarifying products targeted at both the low-speed vehicle and high-speed vehicle markets is underway to ensure that AYRO is targeting the highest value-add components possible within the EV and delivery markets. This holistic examination includes the evaluation of the vehicle component themselves for both the LSV and HSV market segments. An evaluation of AYRO's current partnerships with Club Car, Gallery Carts, and Element Fleet Management is underway to ensure these partnerships are bringing optimized value to the Company and properly leveraging their respective expertise. AYRO is evaluating its cost structure to better align its expenses with its product development cycle. Additionally, the Company will consolidate its Austin manufacturing and office footprints.

09:18 EST Golar LNG announces formation of Cool Company - Golar is pleased to announce the formation of Cool Company, and the entry into a pre-commitment agreement. CoolCo targets to become a growth vehicle and consolidator of modern LNG carriers and provide investors with direct market exposure to an expected continued strength in the LNG freight market. The consummation of the transactions contemplated by the Terms Agreement would result in CoolCo acquiring Golar's 8 TFDE LNG carriers with plans to raise equity and separately list on Euronext Growth in Oslo during Q1 2022. CoolCo is also expected to acquire the commercial and technical organization associated with the operation of Golar's owned and operated shipping and FSRU assets to become a fully integrated operating platform with capacity for fleet growth. The anticipated IPO proceeds will, together with a contemplated debt refinancing, be used to acquire the 8 TFDE vessels from Golar, secure attractive financing and provide CoolCo with working capital to position the company for further growth. Outstanding Contractual Debt associated with the 8 vessels was $858 million as of September 30, 2021. In addition to a cash release, Golar intends to retain approximately 1/3rd of CoolCo as contemplated by the Terms Agreement. Eastern Pacific Shipping, one of the world's largest privately-owned shipping companies, has as part of the Agreement pre-subscribed for $150 million in CoolCo equity based on an average TFDE ship valuation of $145 million, making EPS the largest shareholder of CoolCo. Subject to market conditions, the Terms Agreement contemplates an equity private placement to outside investors during Q1 2022. Alongside Golar, EPS will take an active role in the further development of CoolCo and will chair the Board of Directors. Five listed LNG carrier companies have been taken private during 2021. Remaining listed peers have limited market exposure for modern tonnage. CoolCo aims to provide investors with attractive market exposure, dividend distributions, attractive organic growth and pursue industry consolidation.

09:17 EST RedHill Biopharma announces additional insider buying by senior management - RedHill Biopharma announced that members of its board of directors and senior management, including the company's Chairman & CEO, Dror Ben-Asher, collectively purchased approximately an additional 66,000 American Depositary Shares of RedHill since mid-October, in open-market transactions.

09:16 EST DXC Technology names Kristie Grinnell SVP Chief Information Officer - DXC Technology has appointed Kristie Grinnell as senior vice president and chief information officer, CIO. Grinnell, who previously served as global CIO and vice president for supply chain at General Dynamics Information Technology, GDIT, will report to Chris Drumgoole, DXC's executive vice president and chief operating officer . She succeeds Drumgoole, who was promoted to COO in August. At DXC, Grinnell will lead global IT strategy and operations, responsible for integrating and streamlining systems, implementing new digital capabilities to improve performance and efficiency, and ensuring the stability of DXC's global IT infrastructure, all with the goal of enabling the company to provide superior service and innovation to its customers worldwide.

09:16 EST Retail Opportunity concludes board refreshment, governance review - The Board of Directors of Retail Opportunity Investments (ROIC) announced that it has concluded the Board refreshment and governance review it launched after its 2021 Annual Meeting and has appointed Zabrina Jenkins and Adrienne Banks Pitts as independent directors, effective December 15, 2021, and has adopted a Bylaw amendment to enhance stockholder rights. In addition, director Charles Persico has advised the Board that he will not stand for re-election to the Board at ROIC's next annual meeting. enkins is Senior Vice President and Deputy General Counsel of Starbucks Corporation (SBUX). Ms. Pitts is Managing Director, General Counsel and Corporate Secretary of Loop Capital, LLC, the largest minority-owned investment bank and broker dealer in the United States, including its investment management joint venture with Magic Johnson Enterprises, known as JLC Infrastructure. ROIC also announced that director Charles Persico has advised the Board that he will not stand for re-election to the Board at ROIC's 2022 annual meeting. After that annual meeting, the ROIC Board will consist of nine directors, seven of whom will be independent. ROIC also announced today that the Board has enhanced the rights of stockholders by providing that stockholders may amend the company's Bylaws.

09:13 EST CleanSpark names Vecchiarelli as new Chief Financial Officer - CleanSpark announced that its board of directors has appointed Gary Vecchiarelli Chief Financial Officer of the Company. Vecchiarelli succeeds outgoing CFO, Lori Love. Vecchiarelli was most recently Chief Financial Officer for Imatrex, a high-tech medical imaging solutions company.

09:13 EST Nektar and Eli Lilly announce Phase 1b data for atopic dermatitis candidate - Nektar's (NKTR) partner Eli Lilly (LLY) presented preliminary results from a Lilly-sponsored Phase 1b proof-of-concept study of NKTR-358, a novel T regulatory cell stimulator, in patients with moderate-to-severe atopic dermatitis. Key conclusions from today's preliminary data presentation of the Phase 1b study of NKTR-358 in patients with moderate-to-severe atopic dermatitis include: proof-of-concept data show that NKTR-358 resulted in a dose dependent reduction in Eczema Area and Severity Index scores in patients with moderate-to-severe atopic dermatitis; treatment with NKTR-358 at the 24 ug/kg dose resulted in a 70% maximum reduction in EASI scores at week 12; treatment with NKTR-358 over a 12-week period at the 24 ug/kg Q2W dose resulted in sustained disease control for at least 6 months after last dose demonstrating the potential for NKTR-358 to differentiate from standard of care. NKTR-358 exhibited a similar tolerability profile in the Phase 1b study in atopic dermatitis as shown in prior studies conducted in patients with mild-to-moderate SLE and healthy volunteers.

09:12 EST C3.ai authorizes stock repurchase program, up to $100M over 18 months - C3.ai announced that its Board of Directors has authorized a stock repurchase program of up to $100M of C3 AI's class A common stock over the next 18 months. The timing and number of shares actually purchased under the program will depend on market conditions and applicable legal requirements, among other factors. "We believe strongly in the opportunities ahead for C3 AI, and our potential for creating significant long-term value for all our stakeholders as we execute on our strategic vision," said Thomas M. Siebel, CEO of C3 AI. "We see this as an attractive use of capital while still allowing us to invest in our growth." As of the end of second quarter of fiscal year 2022, C3 AI had approximately $1.1B in cash, cash equivalents, and investments on the balance sheet.

09:10 EST GeoVax Labs announces initiation of Phase 2 trial for COVID-19 vaccine booster - GeoVax Labs announced the initiation of vaccine dosing in the Phase 2 portion of its Phase 1/2 clinical trial of COH04S1, a multi-antigenic SARS-CoV-2 investigational vaccine, designed to target both the spike and nucleocapsid proteins, to evaluate its use as a universal booster to current FDA-approved vaccines. The clinical trial, titled "Phase 1/2 Dose Escalation Study to Evaluate the Safety and Biologically Effective Dose of COH04S1, a Synthetic MVA-based SARS-CoV-2 Vaccine, Administered as One or Two Injections or as a Booster to Healthy Adult Volunteers" is being conducted at City of Hope. The Phase 1 portion of the trial was designed as a dose-escalation safety study in healthy individuals between the ages of 18 to 55, who had not been previously infected with SARS-CoV-2. Follow-up studies of the volunteers are continuing in order to better assess duration of immune responses and scientific presentations, and publications of results are planned for early 2022. The Phase 2 booster study, for which vaccination is now underway, will include 60 healthy individuals, 18 years of age and older, who were previously vaccinated with one of the FDA-approved SARS-CoV-2 mRNA vaccines. The study is designed as a dose-escalation trial to specifically evaluate the safety profile and immunogenicity of COH04S1 as a booster shot. David Dodd, GeoVax President and CEO, added, "We are excited to begin this important study and look forward to sharing progress reports going forward on this trial, as well as the ongoing Phase 2 trial of COH04S1 in immunocompromised and other patients. We believe the COH04S1 vaccine, containing the two antigens, S and N, along with the recognized antibody and cellular immune responses resulting from the MVA approach, has the potential to offer greater booster protection than that from the current vaccines in use, as well as provide a greater degree of protection within immunocompromised patients. In addition, our pan-coronavirus vaccine candidate, GEO-CM04, continues to progress, demonstrating promising preclinical data results."

09:09 EST Mission Produce appoints Shaunte Mears-Watkins to board of directors - Mission Produce announces the appointment of Shaunte Mears-Watkins to its board of directors effective December 14, 2021. Ms. Mears-Watkins was appointed to the class of directors that will stand for election at the company's 2022 Annual Meeting of Stockholders. She currently serves as the Chief Commercial Officer at Clif Bar and Company, a double-digit growth manufacturer in the energy food and drink space.

09:08 EST NextPlay Technologies appoints Gardner, Moosa to board of directors - NextPlay Technologies has appointed two independent directors, Edward "Terry" Gardner, Jr., and Farooq Moosa, to its board of directors. Following the appointments, the board is now composed of 10 members. Gardner is currently a partner at C.J. Lawrence. Moosa currently serves as president and CFO of Avenir Senior Living. Gardner's appointment is effective December 9, 2021 and Moosa's appointment took effect on November 23, 2021.

09:08 EST ModivCare appoints Grover Wray as Chief Human Resources Officer - ModivCare announced the appointment of Grover N Wray as the Company's Chief Human Resources Officer.

09:06 EST Alpha Pro Tech announces $2M expansion of share repurchase program - Alpha Pro Tech announced that its Board of Directors has authorized a $2M expansion of the Company's existing share repurchase program. With this authorized expansion, the Company now has approximately $2.1M available to repurchase shares of the Company's common stock, $0.1M of which remains from the previous expansion, most recently announced in September 2020.

09:06 EST First Quantum Minerals to host virtual Capital Markets Day - First Quantum Minerals announces that it will be hosting a virtual Capital Markets Day on January 18, 2022. This virtual event will feature presentations by Chief Operating Officer, Tristan Pascall, and members of senior management outlining the company's strategy, three-year guidance, organic growth profile, ESG initiatives and capital allocation approach. The three-hour virtual capital markets event will commence at 9:00 EST. The listen-only webcast will be available on First Quantum's website at www.first-quantum.com.

09:05 EST CDW enters new partnership with software optimization platform Clearfind - CDW has finalized a partnership agreement with Clearfind, a platform for enterprise-wide software evaluation and optimization. Under the agreement, CDW will utilize the Clearfind platform to make possible its new data-driven software optimization solution. Three years in the making and launched in October 2020, the Clearfind platform addresses software optimization problems by analyzing the capabilities of an organization's software portfolio and pushing out optimization opportunities as they arise. Using artificial intelligence and a proprietary set of software capabilities, Clearfind categorizes all the software in an organization's ecosystem into three buckets: "Review," "Consolidate" and "Keep."

09:04 EST Exxon, BioAccelergy to explore commercial scale development of bio-base stocks - BioAccelergy Ventures has signed a joint-development agreement with ExxonMobil Research and Engineering Company to progress development of a new bio-base stock for lubricants manufacturing from seed and vegetable oil. The multi-year agreement aims to demonstrate the feasibility of producing bio-base stocks at a cost-effective commercial scale to reduce greenhouse gas emissions. BioAccelergy will provide its expertise in bio-based feed supply, genetic research and advanced catalytic process development. ExxonMobil will leverage its industry-leading knowledge in project management, engineering, manufacturing and marketing base stocks.

09:04 EST BorgWarner enters license agreement with PolyCharge America - BorgWarner is strengthening its inverter capabilities and offerings through an exclusive licensing agreement with PolyCharge America, a startup company formed to deliver disruptive capacitor products. With this agreement, BorgWarner secures exclusive rights to bring the PolyCharge NanoLam capacitors in-house for use in the company's extensive selection of inverters. The capacitors enable high-power inverters to be smaller, lighter and more tolerant to high temperatures. The PolyCharge capacitors will be taken in-house at BorgWarner's Singapore facility.

09:03 EST International Paper to build corrugated packaging plant in Atglen, Pennsylvania - International Paper will build a corrugated packaging plant in Atglen, Pennsylvania. The facility will employ approximately 150 team members. The facility will allow International Paper to expand its Industrial Packaging footprint in the northeastern United States. Construction is set to begin in 1Q22 and the company expects the plant to be fully operational in 1Q23.

09:02 EST MGM Growth raises quarterly dividend to 52.5c per share - On an annualized basis, the dividend of $2.10 represents an increase of 2c per share. This is the 15th dividend increase since MGP's initial public offering in April 2016. The dividend will be payable on January 14, 2022 to shareholders of record as of the close of business on December 31, 2021.

09:01 EST Arthur J. Gallagher acquires Tave Risk Management - Arthur J. Gallagher acquired Chicago-based Tave Risk Management. Terms of the transaction were not disclosed. Founded in 2000, Tave Risk Management is a retail property/casualty broker and risk advisory firm offering a range of risk placement, loss forecasting, risk management cost allocation and risk financing services to large and mid-sized clients across a range of industries, including manufacturing, construction, financial services, nonprofits, museums and universities, as well as high-net-worth private clients. Ruth Tave and her associates will remain in their current location under the direction of Ryan Isaacs, head of Gallagher's Midwest region retail property/casualty brokerage operations.

08:52 EST Universal Electronics announces ITC ruling in its favor in Roku patent case - Universal Electronics (UEIC) announced that the United States International Trade Commission, or ITC, publicly issued its favorable final determination in UEI's patent infringement case against Roku (ROKU), concluding several Roku products infringe a UEI patent and barring the importation and sale of those products. The orders will become final on January 9, 2022, following the expiration of a presidential review period. The ITC's opinion made clear that Roku's products infringe six different claims of UEI's U.S. Patent No. 10,593,196 and rejected Roku's plea to avoid the ITC ban. Referring to UEI's evidence as "substantial," "impressive" and "dispositive," the commission issued a limited exclusion order precluding Roku from importing any infringing "televisions, set top boxes, remote control devices, streaming devices and sound bars."

08:47 EST Intuitive Surgical receives FDA clearance for 8mm SureForm 30 Curved-Tip Stapler - Intuitive announced that the U.S. Food & Drug Administration cleared the company's fully wristed, 8 mm SureForm 30 Curved-Tip Stapler and reloads for use in general, thoracic, gynecologic, urologic, and pediatric surgery. The 8 mm SureForm 30 stapler is expected to launch in the U.S. in 2022, with other countries to follow. It has been designed to help surgeons better visualize and reach anatomy through a combination of the 8 mm diameter instrument shaft and jaws, 120-degree cone of wristed articulation, and the curved tip. As it fits through the 8 mm da Vinci surgical system instrument cannula, the stapler allows different angles for surgeons to approach patient anatomy.

08:39 EST SurgePays enlists Jason Aaron to develop national sales rollout strategy - SurgePays has selected Jason Aaron to consult on the development of the blueprint for building, implementing, and scaling the Company's national sales expansion strategy. He currently serves as senior director, Strategic Partnerships, for Onriva.

08:37 EST Alector appoints Sara Kenkare-Mitra as President, Head of Research, Development - Alector announced the appointment of Sara Kenkare-Mitra, Ph.D., as President and Head of Research and Development. In this newly created role, Dr. Kenkare-Mitra will lead all aspects of the company's immuno-neurology and oncology R&D efforts, including oversight of the research, development, clinical, manufacturing, regulatory, and related functions. Dr. Kenkare-Mitra will report to Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector. Dr. Kenkare-Mitra joins Alector from Genentech where, as Senior Vice President, Development Sciences, she served as a member of the research and development leadership team, overseeing the transition of molecules from discovery to the clinic and their continued translation into medicines through clinical development.

08:36 EST Otonomo Technologies partners with NXP Semiconductors - Otonomo Technologies (OTMO) announced it has joined forces with NXP Semiconductors (NXPI) to accelerate the time-to-value for the data generated at the vehicle edge. The partnership ensures compatibility and business continuity between NXP's S32G vehicle network processors at the vehicle edge and the Otonomo Mobility Intelligence Platform in the cloud, to offer a seamless, secure infrastructure for transferring data from vehicle to cloud. It also enables Otonomo to offer new differentiated and connected vehicle data and mobility insights that can accelerate the time-to-value for secure connected vehicle applications, while breaking down long-standing silos in the automotive industry. "Automakers are under pressure to move faster to deliver new and better-connected cars, and edge computing helps them accomplish that," said Ben Volkow, CEO and Co-founder, Otonomo. "Our collaboration with NXP ensures data captured at the vehicle edge is aligned with the driver needs and adjusted dynamically based on dynamic conditions. As a result, the edge computing data is application-ready; thus enabling the edge data to be more efficient and aligned with privacy and security needs."

08:35 EST Global Technologies provides update on Tersus Power revenue channels - Global Technologies is pleased to provide shareholders an update on Tersus Power's multiple revenue channels. Tersus Power will receive revenue through multiple channels in the hydrogen industry: engineering consulting, sale of the proprietary Modular Hydrogen Fueling Station, sale of standalone components inherit within the Hydrogen Fueling Station and servicing of the Hydrogen Fueling Stations. In the company's first year of business, Tersus Power has generated $1,775,000 from engineering consulting contracts. The company has some of the most talented and sought-after hydrogen engineers in the industry. These engineers are in high demand and Tersus Power will continue to provide hydrogen engineering services to the industry. Tersus Power anticipates receiving most of its revenue through the sale and maintenance of the newly designed proprietary steam methane reformer also known as the Modular Hydrogen Fueling Station. The Company estimates that the sale price for the Hydrogen Fueling Station will be $6.5M per unit. At present, there are 48 hydrogen refueling stations in California. The California Fuel Cell Partnership says the goal is 200 hydrogen stations by 2025 and 1,000 stations in the state are "envisioned" by 2030. Hydrogen demand had been steadily creeping toward 80 million tons/year, has grown more than threefold since 1975 and continues to rise as global demand increases. Tersus Power will receive additional revenue by selling different components of the Modular Hydrogen Fueling Station to the hydrogen industry. For example, selling Tersus Power's proprietary hydrogen storage system as a standalone product. Hydrogen needs to be compressed and stored in tanks for practical handling purposes, and then used as needed. Fuel-cell powered cars run on compressed hydrogen stored in highly pressurized large containers. Processing and storing hydrogen require technology that few companies have direct access to. Tersus Power has developed a hydrogen storage system that is sold with the Hydrogen Fueling Station. With the growing demand for hydrogen fuel, Tersus Power anticipates strong interest in its new storage system.

08:33 EST JNJ announces positive CHMP opinion for booster shot of Covid-19 vaccine - Johnson & Johnson announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a Positive Opinion for use of the company's COVID-19 vaccine as a booster for adults aged 18 and older at least two months after primary vaccination with a single-shot of the Johnson & Johnson COVID-19 vaccine, and as a 'mix and match' booster following primary vaccination with an approved two-shot mRNA COVID-19 vaccine regimen.

08:33 EST Sabre appoints Kurt Ekert as President - Sabre has appointed Kurt Ekert as President of Sabre, separating the roles of president and CEO. The appointment will take effect January 3, 2022. Ekert will oversee all aspects of the company's business and technology operations, including the company's technology transformation. He will report to Sean Menke, who will continue to serve as CEO. Ekert has recently served five years as president and CEO of Carlson Worldwide Travel. He was Executive Vice President and Chief Commercial Officer at Travelport Worldwide.

08:32 EST Tupperware sells real estate associated with beauty business in New Zealand - Tupperware Brands announces the sale and lease-back of its real estate assets associated with its Nutrimetics beauty business in New Zealand. The sale includes two warehouses and a manufacturing facility, and generated gross proceeds of approximately $14M. This transaction is in line with the company's turnaround plan strategy of divesting non-core assets, and follows the company's recently completed sale of its remaining land in Central Florida announced last month.

08:28 EST IT solutions corporation selects Bridgeline Digital's Hawksearch software - Bridgeline Digital announced that their site search product Hawksearch has been selected by an Inc. 5000 IT solutions corporation to support its BigCommerce site's conversion strategy.

08:25 EST Twist shipping synthetic RNA positive controls for Omicron diagnostic tests - Twist Bioscience announced that synthetic RNA positive controls are now available for the SARS-CoV-2 Omicron variants first identified in South Africa. Since the initial discovery, the variant has been identified and is spreading quickly worldwide, with more than 50 countries confirming at least one case as of December 6. "We believe that COVID-19 will become an endemic disease, routinely evolving with new variants continuing to emerge," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. "In addition to the validated positive controls now available for broad distribution, we have been supporting customers who are investigating Omicron's impact on existing vaccines, therapeutics and diagnostic tests, as well as those developing new products to fight all known variants of SARS-CoV-2." Dr. Leproust continued, "While Omicron is the most divergent variant of the virus we have seen to date, it will not be the last. At Twist, we will continue to remain vigilant in monitoring the global landscape and offering new tools to combat COVID-19."

08:23 EST Yorbeau receives scheduled option payment of $750,000 from IAMGold - Yorbeau Resources announced that in order to maintain its option to purchase a 100% interest in the Rouyn property, IAMGOLD Corporation has made the next option cash payment to Yorbeau in the amount of $750,000 corresponding to the fourth in a series of scheduled cash payments to be made to Yorbeau during an Expenditure Period of 48 months. The terms of the definitive option agreement were announced in the Company's press release dated December 17, 2018. Among other commitments, IAMGOLD must make scheduled cash payments in an aggregate amount of C$4M during the Expenditure Period. In the first three years, IAMGOLD has met and exceeded its expenditure obligation of C$6.5M in exploration on the property. In 2022, IAMGOLD plans to continue the evaluation of the resource potential on the project and will complete an additional 6,000 metres of diamond drilling on selected zones of mineralization to support a future Mineral Resource Estimate. In 2022, IAMGOLD plans to continue the evaluation of the resource potential on the project and will complete an additional 6,000 metres of diamond drilling on selected zones of mineralization to support a future Mineral Resource Estimate.

08:20 EST Alta Equipment to acquire Ambrose Equipment, terms to be disclosed at closing - Alta Equipment Group announced that it has entered into a definitive agreement to acquire the assets of Ambrose Equipment, a privately held equipment distributor and an asphalt equipment dealer for more than 33 years, with locations in New Hampshire and Massachusetts. The acquisition expands Alta's construction equipment footprint to 39 locations in 10 states. Ambrose offers a full line of road equipment products and specialty attachments, as well as service, rentals and replacement parts. Ambrose Equipment generated approximately $35M in revenue and had adjusted EBITDA of approximately $3.1M for the trailing-twelve-month period ended August. Terms of the acquisition will be disclosed upon closing. The transaction is expected to close before year-end, subject to customary conditions.

08:19 EST Outlook Therapeutics to present data from NORSE TWO trial - Outlook Therapeutics announced that Francesco Bandello, MD, FEBO, Professor and Chairman of the Department of Ophthalmology, University Vita-Salute, Ospedale San Raffaele, Milan, will present pivotal safety and efficacy data from Outlook Therapeutics' Phase 3 NORSE TWO registration trial for ONS-5010 / LYTENAVA, an investigational ophthalmic formulation of bevacizumab for use in wet age-related macular degeneration. The presentation will take place at the 9th International Congress on OCT and OCT Angiography in Rome/ FLORetina Symposia, on Saturday, December 18, 2021. "The results observed for ONS-5010 in the NORSE TWO trial are potentially of great significance for retinal specialists and their patients suffering from wet AMD," said Dr. Bandello. "I look forward to having an additional approved treatment option for patients that is on-label and specifically formulated and packaged to meet the stringent demands for ophthalmic use."

08:18 EST Silicon Labs, Memfault partner to improve IoT development with embedded devices - Silicon Labs and Memfault, a specialist in cloud-based diagnostics for embedded devices, announced their partnership integrating enhanced development and operations management tools with Silicon Labs' EFR32 and EFM32 devices. The partnership enables advanced MCU-based applications to de-risk development and launch schedules, and confidently ship products that can be monitored and continuously improved in the field. Memfault created a cloud-based embedded device diagnostics platform that solves these serviceability challenges via fleet observability, remote debugging and firmware over-the-air management.

08:17 EST Roblox reports November DAUs 49.4M, up 35% - Roblox released certain metrics for November. Daily active users were 49.4M, up 35% year over year. Hours engaged were 3.6B, up 32% year over year. Estimated bookings for November were between $208M and $211M, up 22%-24% year over year. Estimated average bookings per daily active user was between $4.21 and $4.27, down 8%-9% year over year. Revenue is estimated to be between $184M and $187M, up 84%-87% year over year.

08:16 EST electroCore announces launch of new online shop in the United Kingdom - electroCore announced the launch of an e-commerce shop for patients residing in the United Kingdom. The site, which can be found at www.gammacore.co.uk, requires patients to complete a healthcare questionnaire in order to purchase a gammaCore Sapphire, non-invasive vagus nerve stimulator device online. "We want to make gammaCore more accessible to patients looking to better manage their primary headache conditions. With an estimated 70% of migraineurs being female, the specificity of menstrual migraine is a natural starting point in a new chapter for our business within the online market. We have created a simple assessment process with full clinician oversight offering ongoing customer care as required," stated Karly Hoggard, Director of Global Commercial Development at electroCore. "Many women suffering from migraine symptoms each month expect to live with such symptoms, impacting daily life, work, family and social commitments. We are excited to offer a clinically proven option women looking for solutions to treat their primary headaches, and through this platform we hope to empower people to take ownership of their conditions and regain control."

08:15 EST Codexis launches Codex HiTemp Reverse Transcriptase - Codexis announced the launch of its Codex HiTemp Reverse Transcriptase for use in one-step quantitative reverse transcription PCR, RT-qPCR. RT-qPCR is currently used widely for viral diagnostic tests, including SARS-CoV-2 nucleic acid amplification tests. This enzyme is specifically engineered and optimized for enhanced thermostability and robustness to address known challenges in handling clinical samples. Codex HiTemp Reverse Transcriptase is specifically engineered to provide several key benefits in the RT-qPCR workflow, including: Enhanced thermostability to tackle complicated RNA structures; Improved robustness to address several known challenges when handling clinical samples; Faster turnaround time to complete a reverse transcription reaction in as little as five minutes. "The COVID-19 pandemic has placed rapid and unprecedented demand on PCR testing for viral RNA, driving new supply chain and sample processing workflow challenges," said John Nicols, President and CEO of Codexis. "Given the clear need to create an improved enzyme to reduce reaction time and mitigate some of the well-documented obstacles associated with clinical samples, I am proud of our team for taking action to develop and add Codex(R) HiTemp Reverse Transcriptase to our growing life science enzyme portfolio. We look forward to working with partners to incorporate this Codexis enzyme into their RNA detection toolbox."

08:13 EST Enterprise completes expansion of Acadian nat gas pipeline system in Louisiana - Enterprise Products Partners announced that it recently started commercial service on its new Gillis Lateral pipeline and the associated expansion of its existing Acadian Haynesville Extension system to serve the growing liquefied natural gas market on the Gulf Coast. The approximately 80-mile Gillis Lateral originates near Alexandria, Louisiana on Enterprise's Acadian Haynesville Extension system and extends to third party pipeline interconnects near Gillis, Louisiana, including multiple pipelines serving LNG export facilities. The recently completed Gillis Lateral pipeline has the capability to transport approximately 1 billion cubic feet per day of natural gas. "By leveraging the flexibility of our Acadian system, Enterprise is providing natural gas producers in the growing Haynesville shale, one of the most lucrative natural gas plays in the U.S., with access to the higher valued global LNG market," said Natalie Gayden, senior vice president, Natural Gas Assets for Enterprise's general partner. "This environmentally responsible project will facilitate delivery of affordable, clean-burning U.S. natural gas to developing nations living in energy poverty that may otherwise rely on highly polluting solids, such as wood, coal and animal waste for heating and cooking. The Gillis Lateral is fully subscribed with long-term, firm commitments from shippers." To accommodate the additional volumes, Enterprise increased capacity on its Acadian Haynesville Extension pipeline from 1.8 Bcf/d to 2.1 Bcf/d by increasing horsepower at its Mansfield compressor station in DeSoto Parish. The Legacy Acadian and Haynesville Extension pipelines are part of the Acadian Gas Pipeline system, which is comprised of approximately 1,300 miles of natural gas pipelines and leased underground storage. It links natural gas supplies in Louisiana and offshore Gulf of Mexico to distribution companies, electric utility plants and industrial customers located primarily in the Baton Rouge/New Orleans/Mississippi River corridor area. Enterprise's 378-mile Haynesville Gathering system has a capacity of approximately 1.3 Bcf/d, can treat up to 810 million cubic feet per day of natural gas and provides a significant and reliable source of supply for the Acadian system.

08:13 EST Jiuzi Holdings signs sales cooperation contract with Chinese EV distributor - Jiuzi Holdings has entered into a sales cooperation agreement with Brilliance Xinri Automobile Sales, a brand distributor of electric vehicles in China. Zhejiang Jiuzi will establish a franchise store in Hangzhou City, Zhejiang Province, exclusively for the promotion and sales of the Brilliance Xinri EVs, subject to Brilliance Xinri's review and approval within 30 days upon the store's being set ready for operation. Brilliance Xinri will offer training and cover training-related expenses for the franchise store's sales crew. Zhejiang Jiuzi is entitled to distribute Brilliance Xinri EVs via the franchise store exclusively in Hangzhou City. Specifically, Zhejiang Jiuzi will first order 24 units of Brilliance Xinri EVs and will keep a monthly SKU of 24 Brilliance Xinri EVs during the term of the cooperation. The franchise store will target sales of 20 Brilliance Xinri EV units of per month, as per the Agreement.

08:10 EST Eiger BioPharma's Peginterferon Lambda study in COVID-19 approved to continue - Eiger BioPharmaceuticals announced that the Data Safety Monitoring Board - DSMB - for the Phase 3 TOGETHER study has conducted a second interim futility analysis and recommended continuation of the study. This analysis was based on a sample size of 1,003 patients, randomized to active or placebo. The primary endpoint compares number of extended emergency setting visits, hospitalizations, and/or deaths in treated patients versus placebo. TOGETHER is expected to enroll up to 1,600 patients at high risk for developing complications from progression of COVID-19. TOGETHER is a Phase 3 study evaluating therapeutics in newly diagnosed, high-risk, non-hospitalized patients with COVID-19. The primary endpoint compares number of emergency setting visits, hospitalizations, and/or deaths in treated patients versus placebo through Day 28. TOGETHER is expected to enroll as many as 1,600 patients at high risk for developing complications from progression of COVID-19. TOGETHER is currently recruiting at twelve sites in Brazil.

08:09 EST Walmart to build new fulfillment center in Salt Lake City - Walmart announced plans to build a new fulfillment center in Salt Lake City to support the retailer's e-commerce business. The 1,000,000+ square-foot facility, which is located at 990 N 6550 W, is scheduled to open Summer of 2022 and will create approximately 450 full-time, permanent jobs across the region. The purpose of the facility will be to fulfill online orders placed on Walmart.com. The facility is part of a broader initiative to add more capacity into Walmart's supply chain as the retailer prepares for growth. In Q3 of FY22, Walmart U.S. e-commerce sales grew 8% for the quarter and 87% over the past two years.

08:09 EST BioCardia establishes new manufacturing facility in California - BioCardia announces that it has entered into a long-term lease for a new facility in Sunnyvale, California. This facility is being built out to support the manufacturing of BioCardia's cell and device products and product candidates across the Company's therapeutic pipeline. The new facility is expected to provide manufacturing capabilities across BioCardia's portfolio, including its CardiAMP Cell Therapy Systems, NK1R+ mesenchymal stem cells, and Biotherapeutic Delivery Devices, with the ultimate goal of supporting clinical trials in multiple programs and early commercial activities. "We have always believed that manufacturing during development needs to be kept close to capture new insights and innovate rapidly. Controlling manufacturing at this stage helps accelerate the development of our cell-based medicines, which we also believe is a key differentiator of BioCardia from many other cellular therapeutics companies," said Peter Altman, BioCardia's President and CEO. "We expect to soon see all four of the programs we discuss publicly in the clinic helping patients, with our in-house facilities providing the material."

08:08 EST Healthcare Triangle's MEDITECH-as-a-Service selected by Sage Memorial Hospital - Healthcare Triangle's expertise and experience in MEDITECH's Expanse/MaaS software helped Sage Memorial accelerate their MaaS implementation and successful transition from paper and free-text notes for nursing staff, enabling structured data assessments and electronic care planning. The MEDITECH MaaS Platform offered an efficient implementation and cost-effective pricing on a modern technology platform. HCTI guided the implementation of the electronic 837 claim format. HCTI led the effort in coordinating between the Sage team, MEDITECH, and the claims clearinghouse so that claim data could flow smoothly from one system to another. HCTI guided the Sage team to focus on implementing the features best suited for their needs. HCTI assisted Sage in setting up and optimizing worklist functionality, replacing paper reports previously required to manage and track daily work.

08:07 EST Pyxis Oncology to be added to Russell 2000 Index - Pyxis Oncology announced that the company will be added to the Russell 2000 Index, effective after the U.S. market opens on December 20, 2021, according to the preliminary list of IPO additions to the Russell indexes. Membership in the Russell 2000 Index, which remains in place until the next reconstitution, is based on membership in the broad-market Russell 3000 Index. The stock will also be automatically added to the appropriate growth and value indexes.

08:07 EST Reinsurance Group announces longevity reinsurance deal with Aegon Netherlands - Reinsurance Group of America announced the completion of a longevity reinsurance transaction with Aegon . The reinsurance transaction covers an in-force portfolio of its Dutch business with approximately EUR 7B of underlying reserves. "We value our long-standing relationship with Aegon, and we are proud to continue to collaborate with them to help them to actively manage their risk and capital position," said Simon Wainwright, Executive Vice President, Head of EMEA, RGA. "Partnering with our clients to create customized solutions has led to a standout year in the Netherlands, and we look forward to continued growth in our longevity business in continental Europe." "RGA is a strategic partner for Aegon globally and in the Netherlands," said Allegra van Hovell-Patrizi, CEO of Aegon the Netherlands. "Their local team, with in-depth knowledge of the market supported by their global experts, worked closely with us to tailor the agreement to meet our specific needs, and we appreciate their dedication in executing this transaction." The transaction is effective December 31. Additional terms of the transaction are not being disclosed.

08:06 EST Canopy Growth divests pharmaceutical C3 Cannabinoid Compound Company - Canopy Growth has entered into an agreement to divest its subsidiary business, C Cannabinoid Compound Company, to Dermapharm Holding, a European pharmaceutical company headquartered in Grunwald, Germany. The C business develops and manufactures pharmaceutical products and is comprised of Spectrum Therapeutics GmbH, based in Neumarkt-in-der-Oberpfalz, Germany, THC Pharm GmbH The Health Concept, based in Frankfurt, Germany, and Spectrum Therapeutics Austria GmbH, based in Vienna, Austria. As a result of the divesture, Canopy Growth is expected to avoid future operational complexities associated with C and is significantly reducing short-term capital investment requirements. With the divesture of C, Canopy Growth is also eliminating its obligation of separating C3 operations from those of its prior owner, Bionorica SE. As a result, the company is expected to avoid future operational complexities and is reducing short-term capital investment requirements by over C$50M. An upfront payment of EUR80M, approx. C$115.5M1, subject to customary cash and debt adjustments, will be made upon the closing of the transaction in addition to an earnout payment of up to EUR42.6M, approx. C$61.4M1, subject to the achievement of select milestones by the C business. The transaction is expected to close by January 31, 2022.

08:05 EST Aerovate announces initiation of IMPAHCT Phase 2b/Phase 3 trial of AV-101 - Aerovate Therapeutics announced the initiation of its Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial, IMPAHCT., Phase 2b/Phase 3 trial to evaluate the safety and efficacy of AV-101 in adult patients with Pulmonary Arterial Hypertension, PAH. "We are excited and humbled to initiate this Phase 2b/Phase 3 trial of AV-101," said Tim Noyes, Chief Executive Officer at Aerovate. "Starting enrollment represents an important milestone for Aerovate Therapeutics and advances our goal of improving the lives of patients suffering from rare cardiovascular diseases." Aerovate expects to report top-line results from the Phase 2b portion of IMPAHCT in mid-2023.

08:05 EST Walgreens, VillageMD open nine primary care practices in San Antonio - Walgreens Boots Alliance and VillageMD announced plans to expand into San Antonio with the opening of nine Village Medical at Walgreens primary care practices over the next year. These openings represent expansion into the fifth major market in Texas, following Houston, El Paso, Austin and Dallas. Through the Walgreens and VillageMD coordinated care model, patients receive full-service primary care alongside and pharmacy services.

08:04 EST BIO-key launches next generation of PortalGuard IDass platform Admin Panel - BIO-key International introduced the next generation of its PortalGuard Identity-as-a-Service platform Admin Panel experience to enhance the ability of IT teams to manage and upgrade their IAM strategies. The improved PortalGuard IDaaS Admin Panel provides a simple, centralized interface for common IAM workflows and management of the platform that eliminates inefficiencies and delivers time savings for busy IT teams.

08:03 EST NextGen Healthcare CMO Betty Rabinowitz to retire, Robert Murry to succeed - NextGen Healthcare announced the retirement of its chief medical officer, Betty Rabinowitz, effective December 31. Rabinowitz joined the company in 2017, following her role as one of the founders and former CEO of EagleDream Health, the cloud-based analytics and population management solution acquired by NextGen Healthcare. The company also announced that, following an external and internal search, its chief medical Informatics officer Robert Murry has been promoted to chief medical officer. Murry has been with NextGen Healthcare since 2012 and has guided the company's strategy and vision for select products and services.

07:54 EST Altair Engineering acquires UK-based World Programming - Altair acquired World Programming, a UK-based technology company specializing in data analytics software used by companies including financial services and insurance organizations. World Programming's platform supports development and execution of multi-language software solutions leveraging popular languages used in data science including Python, R, and the SAS language in a single program. World Programming brings a customer base of approximately 500 enterprise customers worldwide. World Programming's software will be integrated into Altair's data analytics solutions suite and available via Altair Units.

07:51 EST Lowe's sees FY22 total share repurchases $12B - Sees FY22 ROIC of approximately 35%; Effective income tax rate of approximately 25%; capital expenditures of approximately $2B; Operating income as a percentage of sales (operating margin) of 12.5%-12.8%.

07:43 EST Hudbay Minerals announces initial mineral resource estimate at Copper World - Hudbay Minerals announced a National Instrument 43-101 initial mineral resource estimate for the recently discovered Copper World deposits located near the company's Rosemont copper project in Arizona. The 100% owned Copper World project is located in close proximity to the 100% owned Rosemont deposit, with mineralization closer to surface than Rosemont. The Copper World project consists of seven deposits extending over seven kilometres, including Bolsa, Broad Top Butte, Copper World, Peach, Elgin, South Limb and North Limb. In October 2020, Hudbay began condemnation and exploration drilling over the company's patented private land claims at Copper World and, following encouraging early results, Hudbay expanded the exploration drill program. The initial drill results were announced in March 2021, including four deposits with the potential to be a viable open pit operation. Since then, Hudbay's exploration program at Copper World has continued to define and extend seven mineral deposits hosting both oxide and sulphide copper mineralization at shallow depths over a seven-kilometre strike area. The deposits are located northwest of and in continuity with the Rosemont deposit and are predominantly located on Hudbay's wholly owned private land mining claims. The mineralization consists of both skarn and porphyry copper sulphides with a significant oxidized component along a regional fault along the west side of the Rosemont, Bolsa and Broad Top Butte deposits known as the Backbone Fault. The Copper World deposits contain higher grade mineralization that often starts at or very near surface. This is specifically observed at the Peach-Elgin, Broad Top Butte and Bolsa deposits where significant higher-grade tonnage has the potential to be mined with minimum waste stripping during the initial years of mining The resource estimate for Copper World includes drilling completed since the last exploration update on September 22, 2021. The recent drilling activities have focused on filling the drilling gap between the Bolsa and Rosemont deposits and have been successful in continuing to delineate higher grade mineralization. The drilling gap has now been reduced to 300 feet from 1,500 feet, and the drilling has extended the Bolsa deposit to the south. Four drill rigs continue to turn at site to conduct infill drilling and to support future economic studies. Approximately 33 million tonnes of inferred mineral resources at the Bolsa deposit were considered to be waste in the resource pit shell used for the NI 43-101 Technical Report Feasibility Study for Rosemont dated March 30, 2017. For that study, these tonnes were accounted for as pre-stripping since there were no mineralized intersections available at the time. Any ability to convert Bolsa mineral resources to reserves would be expected to result in less waste being mined at Rosemont, thereby reducing costs and energy consumption per tonne of ore mined. It is expected that additional synergies will be identified as Hudbay continues to close the drilling gap between Bolsa and Rosemont. The Rosemont deposit also contains oxide mineralization that was previously classified as waste, which may be able to be processed with the oxide mineralization at Copper World, further reducing costs and energy consumption per tonne of ore mined at Rosemont. Preliminary Economic Assessment on Track for the First Half of 2022: The technical studies for Copper World are well-advanced and the results will be incorporated into a Preliminary Economic Assessmentcontemplating the development of the Copper World deposits in conjunction with the Rosemont deposit. The company expects to publish the PEA results in a NI 43-101 Technical Report in the first half of 2022. The PEA is also expected to reflect preliminary expectations of potential synergies between Copper World and Rosemont. The Rosemont deposit is one of the world's best undeveloped copper projects with proven and probable mineral reserves of 537 million tonnes at 0.45% copper and additional measured and indicated mineral resources, exclusive of reserves, of 536 million tonnes at 0.29% copper. Hudbay is also completing a review of the Rosemont resource model in the 2017 Feasibility Study based on the recent knowledge gained from the shallow drilling conducted at Copper World and notably at Bolsa, as described above. The objective is to investigate opportunities to reduce some of the grade smoothing inherent in the resource modeling methodology used in 2017 for Rosemont. Private Land Operation Permitting Underway: Hudbay holds approximately 4,500 acres of private land and patented mining claims to support an operation entirely on private land. In October, Hudbay received approval from the Arizona State Mine Inspector for its Mined Land Reclamation Plan for Copper World after applying for the MLRP in June 2021. The MLRP approval includes the requirement for reclamation cost bonding prior to initiating work on the company's private lands and represents the first step in the state-level permitting process for a private land operation. The aquifer protection permit and air quality permit are the key state-level permits required for a private land operation, which, along with other minor permits, are expected to be advanced in 2022 pending positive economic studies for Copper World. Hudbay has previously received the aquifer protection and air quality permits for Rosemont and these permits have been successfully upheld through litigation. Continued Exploration Success and 2022 Plans for Further Drilling and Economic Studies: There remain opportunities for extension of the mineralization discovered at the Copper World and Bolsa deposits. The objectives of the current drilling program, which will continue in 2022, is to convert a large portion of the inferred mineral resources to the indicated category, convert some of the indicated mineral resources to the measured category, to test the potential connections between Broad Top Butte and Bolsa and between Bolsa and Rosemont, to test for extensions of the Copper World deposit, and to test for other discrete mineralized bodies in between the known deposits. Hudbay is also planning to advance a pre-feasibility study in 2022 after the completion of the PEA. Activities to support the PEA will include additional technical studies and drilling at Copper World.

07:39 EST Intelligent Systems announces name change to CoreCard - Intelligent Systems announced that it is changing its name to CoreCard Corporation. The Company anticipates its common stock will begin trading using new ticker symbol "CCRD" at the commencement of trading on December 29, 2021, and that its common stock will continue to trade on the NYSE under the symbol "INS" until the closing of trading on December 28, 2021. The Company's corporate structure will not be changing, nor will its financial reporting.

07:36 EST Document Security opens new office in Sacramento - DSS announced the opening of a new office in Sacramento, California to serve as the home office for DSS Wealth Management and DSS AmericaFirst Quantitative Funds. "This is an exciting area of our business with significant rapid growth potential," stated Jason Grady, COO of DSS. "Bringing the DSS Wealth Management and DSS AmericaFirst teams together in Sacramento should accelerate our sales and marketing initiatives while the ongoing expansion of our product portfolio with innovative quantitative strategies will enable us to reach an even broader mix of investors."

07:35 EST CSL: EMA grants approval for etranacogene dezaparvovec MAA - CSL Behring announced that the European Medicines Agency has granted its approval for an accelerated assessment request for etranacogene dezaparvovec Marketing Authorisation Application. Etranacogene dezaparvovec is an investigational gene therapy for people with haemophilia B, a life-threatening bleeding disorder, and is currently being studied in the Phase 3 HOPE-B clinical trial.

07:34 EST ABM announces Elevate Investment Program - Building upon the success of the Company's Vision 2020 initiative, ABM will discuss today at its Virtual Investor Day a multi-year comprehensive investment initiative, called Elevate. Elevate is a transformational program intended to enhance the Company's strategic position; leverage the advantages of leading-edge technologies, inclusive of data and analytics; capture incremental growth and profit opportunities arising from shifting demographics, rapidly changing workplace dynamics and the need for increased corporate sustainability. Elevate investments are expected to accelerate the Company's organic growth, strengthen profitability and create a more rewarding experience for both clients and employees. The total Elevate investment is estimated to be $150 million to $175 million and most of these discrete investments will be reported as items impacting comparability. Elevate is expected to be largely completed by the end of fiscal 2025. In fiscal 2022, the Company expects its Elevate investment will be $80 million, including $72 million in discrete expenses and $8 million in capital expenditures. This initial investment will significantly advance the implementation of the Company's digital transformation initiative, enabling lower levels of investment in subsequent years.

07:33 EST Microbot Medical achieves design freeze of the LIBERTY Robotic System - Microbot Medical achieved the design freeze objective for the LIBERTY Robotic System. This milestone demonstrates the continued progress towards the commercialization of the world's first fully disposable robotic system. With the design freeze, in accordance with the Company's previously provided timeline, the next meaningful milestone is the filing of the pre-submission with the U.S. Food and Drug Administration during the first quarter of 2022. "This critical milestone brings us one step closer to our ultimate goal of commercializing the LIBERTY Robotic System, which has the potential to change the way surgical robotics are viewed, from large capital equipment that burden the healthcare system to a disposable and integrated system in the treatment flow," commented Harel Gadot, Chairman, CEO and President. "Meeting this meaningful milestone, within the timeframe we previously provided, gives us the confidence we will continue in our path toward commercialization. I want to commend our engineering team for their ingenuity and dedication to executing this milestone on time, as well as the valuable input and partnership by our Scientific Advisory Board. We are now positioned to pursue additional near-term objectives, including the FDA pre-submission, and securing clinical sites to support any regulatory requirements."

07:32 EST Cybin receives notice of allowance from USPTO for CYB004 patent - Cybin announced that it has been awarded a notice of allowance from the U.S. Patent and Trademark Office, or USPTO, for patent application No. 17/394,038 related to CYB004, the company's investigational deuterated psychedelic tryptamine compound for the potential treatment of anxiety disorders. The allowed claims include other forms of deuterated psychedelic tryptamine, notably certain deuterated forms of DMT and 5-MeO-DMT. The patent, which is expected to expire in 2041 before consideration of any patent term extensions, covers composition of matter for the CYB004 drug substance as a putative new chemical entity.

07:31 EST Alliance Data reports November net charge offs 4.6% vs. 4.1% last month - Reports November delinquency ration 3.9% vs. 3.9% last month.

07:27 EST Cabot Microelectronics trading halted, news pending

07:26 EST Osisko Mining announces results from drill program at Windfall project - Osisko Mining provides new analytical results from the ongoing drill program at its 100% owned Windfall gold project located in the Abitibi greenstone belt, Urban Township, Eeyou Istchee James Bay, Quebec. Significant new analytical results presented below include 35 intercepts in 14 drill holes and 9 wedges. The infill intercepts are located inside defined February 2021 mineral resource estimate blocks. The expansion intercepts are located outside the February 2021 MRE blocks and either expand resource wireframes or are in a defined zone or corridor but do not yet correlate to a specific wireframe. Selected high-grade intercepts include 118 g/t Au over 2.3 metres in WST-21-0784; 96.2 g/t Au over 2.6 metres in OSK-W-21-2629; 108 g/t Au over 2.0 metres in OSK-W-21-2633; 83.5 g/t Au over 2.0 metres in WST-21-0855B; 37.8 g/t Au over 2.6 metres in OSK-W-21-2621.

07:23 EST Santhera Pharmaceuticals shareholders approve all board proposals at EGM - Santhera Pharmaceuticals announces that its shareholders have approved all proposals by the Board of Directors at the Extraordinary General Meeting at the Company's domicile in Pratteln, Switzerland. In total, 15,454,014 shares equaling 28.3% of the Company's share capital were represented. Santhera will require additional funding during 2022 to enable continued pipeline development and preparations for the commercialization of vamorolone. With their approval of all proposed capital increases at today's EGM, Santhera's shareholders gave the Company a flexible financing instrument and enabled the Board of Directors to issue new shares for financing purposes and to enter into equity or equity-based financings or re-financings, all at a moment favorable to Santhera and complementary to potential non-dilutive funding arrangements. The shareholders' approvals included: Ordinary capital increase by CHF 20,000,000 to CHF 74,607,810 by issuing 20,000,000 fully paid-in registered shares with a par value of CHF 1 each. Increase of authorized capital from CHF 11,862,424 by CHF 15,441,481 to CHF 27,303,905 and its extension until December 14, 2023. Increase of conditional capital for financings by CHF 15,038,128 to CHF 21,878,228. As previously announced, both the authorized capital and the conditional capital for financing would be increased again in a second step by CHF 10,000,000 each if the ordinary capital increase can be fully consummated within three months from December 15, 2021, the date of the EGM.

07:21 EST Standard Lithium signs LOI with Koch Engineered to support lithium project - Standard Lithium announced it has signed a Letter of Intent, LOI, with Koch Engineered Solutions for support with pre-front end engineering design at the Company's proposed first commercial plant located at the Lanxess facility in southern Arkansas. The intent of the LOI is to organize and use several business units under the KES umbrella to form an Integrated Project Management Team, IPMT, that will help Standard Lithium to execute key pre-FEED work. The IPMT will largely draw on strategically aligned resources from Koch Project Solutions, Koch Separation Solutions and Optimized Process Designs. The IPMT will be structured to assist the Company in evaluating process scale-up solutions, equipment options, preliminary engineering design, scheduling, budgeting and other project management activities relating to the first commercial lithium plant proposed at the Lanxess facility in southern Arkansas. The proposed site for the first commercial facility currently houses the Company's continuously operating pre-commercial Direct Lithium Extraction Demonstration Plant.

07:20 EST CI Financial acquires CPWM and strategic stake in Columbia Pacific Advisors - CI Financial and Columbia Pacific of Seattle announced a strategic relationship in which CI will invest in the continued growth of Columbia Pacific's world-class wealth management and alternative asset management firms. Under the agreements, CI will acquire Columbia Pacific Wealth Management, CPWM, which has $6.4B in total assets under management and provides a full range of wealth management solutions to high-net-worth and ultra-high-net-worth clients on the West Coast and across the United States. Additionally, CI will acquire a minority stake in Columbia Pacific Advisors, an alternative asset management firm that manages $3.5B in total assets under management across a broad selection of institutional-caliber real estate private equity, direct lending, opportunistic and hedged strategies. "Columbia Pacific has built remarkable wealth management and alternative asset management businesses centered on delivering the best possible outcomes for their clients and investors," said Kurt MacAlpine, Chief Executive Officer of CI Financial. "Their success has been driven by highly skilled and committed leadership teams with extensive experience in financial services and other businesses. The cultural alignment and shared vision for growth make this an exciting opportunity for CI as we continue to attract the best firms in the business to CI Private Wealth."

07:18 EST AxoGen sponsors 2022 Donate Life Rose Parade Float - Axogen announced that nerve repair patient Christopher Brown has been selected to ride on the 2022 Donate Life Rose Parade Float. Additionally, organ and tissue donor Paul Flanders will be honored through a floragraph that will adorn the float. The parade will be held in Pasadena, CA on New Year's Day as part of the annual Tournament of Roses celebration. This is the ninth year that Axogen has co-sponsored the Donate Life float to help raise awareness for the importance of organ and tissue donation. Axogen is proud to honor and celebrate Paul and Chris as part of this year's event. Paul, a newspaperman from the Northshore of Massachusetts, was an organ and tissue donor whose selfless gift of life has helped numerous organ and tissue recipients

07:16 EST Lexington Realty announces name change to LXP Industrial Trust - Lexington Realty Trust announced a corporate rebranding and name change to LXP Industrial Trust. In connection with the rebranding, LXP also unveiled a new logo and launched a new website at www.lxp.com. LXP's new name and logo reflect its focus on industrial real estate investments as the Company completes its transition from a diversified net-lease REIT into a primarily single-tenant industrial REIT focused on high-quality warehouse and distribution assets in key U.S. logistics markets. T. Wilson Eglin, LXP's Chairman and CEO, commented, "We are excited to launch our new corporate rebranding, which more accurately reflects LXP's portfolio focus and growth strategy. The rebranding is an important milestone in the evolution of LXP and underscores our success in transforming the company from a diversified net-lease REIT to a primarily single-tenant industrial REIT." LXP will continue to trade under its ticker symbol "LXP." The name change will take effect with the New York Stock Exchange in 10 days.

07:15 EST Sprott updates leadership team with ten new managing directors - Sprott announced the promotion of 10 new Managing Directors, in recognition of their accomplishments and ongoing contributions to the Company's success. In addition, Maria Smirnova has been named Chief Investment Officer of Sprott Asset Management LP. Sprott's new Managing Directors: Samay Bhachech, Managing Director, Financial Controls, Treasury, Planning & Analysis, Sprott Inc.; Lisa Edwards, Managing Director, Sprott Inc.; Chief Compliance & Operations Officer, Sprott Capital Partners; Doug Groh, Managing Director, Sprott Inc.; Senior Portfolio Manager, Sprott Asset Management; Shree Kargutkar, Managing Director, Sprott Inc.; Portfolio Manager, Sprott Asset Management; Sarah-Jane Martin, Managing Director, Chief Talent Officer, Sprott Inc.; Jason Mayer, Managing Director, Sprott Inc.; Senior Portfolio Manager, Sprott Asset Management; Lara Misner, Managing Director, Head of Enterprise Risk, Sprott Inc.; Chief Compliance Officer, Sprott Asset Management; Maria Smirnova, Managing Director, Sprott Inc.; Senior Portfolio Manager & Chief Investment Officer, Sprott Asset Management; J'aime Spork, Managing Director, Sprott Inc.; Head Trader, Sprott Asset Management; Justin Tolman, Managing Director, Sprott Inc., Economic Geologist, Sprott Global Resource Investments Ltd.

07:14 EST Glory Star New Media provides operational updates - Glory Star New Media announced that as of November 30, the total installed base of CHEERS ecosystem users reached 260 million, a 54% increase versus the 2020 installed base of 169 million users. Monthly Active Users from January to November 2021 was 44 million users in average, a 20% increase from the same period in 2020. The CHEERS e-mall had an installed base of over 11 million with November 2021 MAU of 3.4 million users. This equated to Gross Merchandise Value of over RMB2.5B, up 260% from the same period in 2020. Additionally, the repurchase rate of users reached 35%. The company provided ab update in conjunction with the build-out of the Metaverse Experience Centers, The company is developing its closed-loop business model within the CHEERS video platform to further monetize its assets by converting traffic into leads and sales. Through leveraging the closed-loop model, Glory Star expects to further facilitate the company's long-term growth prospects, consolidate the e-commerce space, and enhance user experience to strengthen the company's core competencies. The company will also adopt NFT technology to help guard the copyrights of the platform's original content.

07:13 EST Ketamine One announces lifting of management cease trade order - KetamineOne Capital is pleased to announce that its management cease trade order granted by the British Columbia Securities Commission on November 1, 2021, was lifted effective immediately following the filing on SEDAR on December 13, 2021 of the Company's audited annual financial statements and accompanying management's discussion and analysis for the fiscal year ended July 31, 2021.

07:11 EST Skylight Health completes divestiture of legacy business to New Frontier Data - Skylight Health Group announced the closing and divestiture of its Canna Care Docs and Relaxed Clarity to New Frontier Data. The legacy business was engaged in clinical evaluations and recommendations for patients seeking medical cannabis for state regulated conditions; New Frontier Data purchased 100% of the Legacy Business for a total cash consideration of USD $8,628,000 set forth in the terms below; Skylight will utilize cash proceeds from the sale to purchase additional primary care practices as well as working capital; and This divestiture allows Skylight to continue its focus on its core business of the traditional healthcare market and support of value-based primary care models. The transaction closed on December 15, 2021; terms of the transaction are a total cash consideration of $8.628M. The closing payment of $4M is subject to customary working capital holdbacks, with the remaining balance paid over three installments at 12 months, 18 months, and 24 months from the date of closing. Finally, the Skylight Health Group announces the grants of 219,318 shares issued to directors pursuant to the restricted stock unit plan as part of their annual compensation. Additional grants include 60,000 share purchase options to employees which expire in five years as well as 50,000 share purchase options to consultants that expire in 15 months. All share units and purchase options, as applicable, are priced at CAD $1.78.

07:10 EST Valens Semiconductor, Sumitomo Electric partner on MIPI A-PHY technology - Valens Semiconductor announced that they are collaborating in the field of A-PHY technology and deployments. The companies will work together to ensure that Sumitomo Electric's wiring harness systems meet the channel requirements of the A-PHY specification, while Valens will add the Sumitomo Electric cable assembly and matching on-board connectors as an ordering option for its VA70XX customer evaluation kits. The cooperation will streamline the deployment of MIPI A-PHY technology across the automotive industry.

07:09 EST Points International, EVA Air enter multi-year collaboration - EVA Air, and Points have entered into a new multi-year collaboration to introduce a series of member benefits that will increase customer engagement and generate additional ancillary revenue streams for the carrier via the Infinity MileageLands program.

07:08 EST Nuvation Bio's NUV-422 granted FDA Fast Track Designation for glioblastoma - Nuvation Bio's NUV-422, a cyclin-dependent kinase 2/4/6 inhibitor, has been granted Fast Track designation by the FDA for the treatment of patients with high-grade gliomas, including glioblastoma multiforme. NUV-422 received Orphan Drug Designation for the treatment of patients with malignant gliomas from the FDA in 1Q21. NUV-422 is the company's lead investigational CDK2/4/6 inhibitor program that works to overcome the limitations of CDK4/6 inhibitors. Preclinical studies have shown that NUV-422 has favorable blood-brain barrier penetration. In addition to high grade gliomas, NUV-422 is currently being studied in HR+ HER2- advanced breast cancer and metastatic castration resistant prostate cancer.

07:08 EST Points International enables new option for EVA Air loyalty members - Between now and January 13, 2022, EVA's Infinity MileageLands members can receive up to 65% in additional bonus award miles when they buy miles with Purchase Miles. This time-limited promotion has been launched to celebrate the introduction of the new member benefit, which has been implemented in collaboration with global leader in loyalty commerce, Points. Rob MacLean, CEO of Points, commented on the news, "We are extremely pleased to be partnering with EVA Air and to be helping their most loyal customers to enjoy more convenience and value when planning their next trip away. With Purchase Miles, members can ensure that their balance is ready for their next flight reward. Plus, if they take advantage of the service right now, they'll benefit from additional bonus miles; making vacation planning that bit easier so they can get away even sooner."

07:06 EST Lennox sees FY21 CapEx $135M - Sees FY21: Free cash flow of approximately $400M; Stock repurchases of $600M; An effective tax rate of approximately 20% on an adjusted basis for the full year.

07:05 EST Lennox sees FY22 CapEx $125M - Sees FY22: Free cash flow of approximately $400M; Stock repurchases of $400M; An effective tax rate of approximately 20% on an adjusted basis for the full year.

07:05 EST Entegris to acquire CMC Materials for $6.5B in cash and shares, sees accretion - Entegris (ENTG) and CMC Materials (CCMP) announced a definitive merger agreement under which Entegris will acquire CMC Materials in a cash and stock transaction with an enterprise value of approximately $6.5B. Under the terms of the agreement, CMC Materials shareholders will receive $133.00 in cash and 0.4506 shares of Entegris common stock for each share of CMC Materials common stock they own. The total per share consideration represents a 35% premium over CMC Materials' closing price on December 14 and a 38% premium to the 10-day volume weighted average share price. Upon completion of the transaction, Entegris shareholders will own approximately 91% of the combined company and CMC Materials shareholders will own approximately 9%. The transaction is expected to be significantly accretive to non-GAAP EPS within the first year post-closing. Entegris expects to realize $75M in run-rate cost synergies and $40M in CapEx synergies within 12 to 18 months from the closing of the transaction. Entegris is targeting pro forma adjusted gross leverage of approximately 4.0x at closing. The transaction is to be financed with a combination of equity issued to CMC Materials, new debt and cash on hand. Entegris has obtained fully committed debt financing. The transaction is not subject to a financing condition. The transaction is expected to close in the second half of 2022, subject to the satisfaction of customary closing conditions, including regulatory approvals and approval by CMC Materials shareholders.

07:03 EST OneWater enters agreement ot acquire majority interest in Quality Boats - OneWater Marin announced that it has entered into a definitive agreement to acquire a majority interest, in Quality Boats.For the full calendar year 2021, Quality Boats is expected to generate approximately $140M in sales and $20M in EBITDA. The transaction is expected to be immediately accretive to OneWater. "We could not be more excited to welcome the Quality Boats team into the OneWater family. Their significant presence in one of the hottest boating markets in the US and commitment to quality are just a few of the reasons why Quality Boats is an award-winning dealership group and a fantastic fit for the OneWater family," said Austin Singleton, Chief Executive Officer for OneWater. The transaction is expected to close in the next 90 days, and is subject to usual and customary closing conditions. OneWater is anticipated to acquire an 80% interest in Quality Boats, while the Sellers, David and Dan Bair, will retain the remaining interest. OneWater has obtained an option to acquire the remaining 20% interest at a stated price, and at its sole discretion, for a period of five years.

06:55 EST Medtronic receives warning letter from FDA regarding California facility - Medtronic announced it received a warning letter from the FDA on December 9 for the company's Northridge, California facility, the headquarters for its Diabetes Business. The warning letter was issued following an inspection that concluded in July related to recalls of the MiniMed 600 series insulin infusion pump, and a remote controller device for MiniMed 508 and Paradigm pumps. The warning letter focuses on the inadequacy ofspecific medical device quality system requirements at the Northridge facility in the areas of risk assessment, corrective and preventive action, complaint handling, device recalls, and reporting of adverse events.

06:47 EST KULR Technology granted three-year battery safety deployment order - KULR Receives Three-Year Multi-Million Dollar Battery Safety Deployment Order from Volta Energy Products KULR Technology received a three-year multi-million dollar deployment order for its Passive Propagation Resistant solution suite from Volta Energy Products, a subsidiary of Viridi Parente. The PPR solution will be used for Volta's stationary and certain mobile lithium-ion battery power systems. The initial deployment order totals approximately $1.6M for immediate delivery with higher volume shipments expected throughout 2022 for KULR's PPR solution. This order represents KULR's first PPR order of commercial deployment in a stationary energy storage product.

06:41 EST Accenture announces intent to acquire AFD.TECH, terms not disclosed - Accenture has announced its intent to acquire AFD.TECH, an independent network services company specializing in network engineering, operations and business services. Financial terms of the transaction are not being disclosed. This acquisition would add more than 1,600 highly skilled professionals to Accenture globally, along with multidisciplinary capabilities across engineering, design, deployment, and operation of next generation networks, such as 5G and fiber.

06:34 EST ViewRay receives FDA clearance for MRIdian features - ViewRay announced that the company received FDA 510(k) clearance for its next generation of MRI-guided radiation therapy features, focused on enhancing on-table adaptive workflow and expanding clinical utility. MRIdian A3i includes a suite of new features to streamline on-table adaptive workflow and provide the potential to reduce treatment times, along with a new brain treatment package expanding clinical utility into cranial stereotactic radiosurgery and stereotactic radiation therapy.

06:32 EST BitNile authorizes stock repurchase program of up to $50M - BitNile has authorized a stock repurchase program under which BitNile may repurchase up to $50M of its outstanding common stock over a three-year period commencing December 15, 2021. The Rule 10b5-1 Plan will allow the company to execute trades during periods when it would ordinarily not be permitted to do so because it may be in possession of material non-public information, because of insider trading laws or self-imposed trading blackout periods. Under the Rule 10b5-1 Plan, the executing broker would have the authority, under the prices, terms and limitations set forth in the Rule 10b5-1 Plan, including compliance with Rule 10b-18 of the Exchange Act, to repurchase shares on the company's behalf. The company intends to finance the repurchases from several sources, including excess cash flow from operations, when available, existing cash from the company's balance sheet, and proceeds from future borrowing arrangements or financings. The repurchase program is for three years,

06:09 EST KKR acquires GBP 300M stake in PureGym - PureGym, a European gym operator, and KKR announced that KKR will make a GBP 300M equity investment in PureGym to support and fund PureGym's expansion plans. KKR will become a significant minority investor in the business alongside management and Leonard Green & Partners, who retain a majority ownership position, PureGym said in a statement.

06:02 EST Canaan secures purchase order for 30,000 Bitcoin mining machines - Canaan announced that it has secured a purchase order from Genesis Digital Assets for 30,000 units of its Avalon Bitcoin mining machines. In August, Canaan granted Genesis Digital Assets an option to purchase up to 180,000 additional Bitcoin mining machines along with its original sales contract of 20,000 machines. The order represents the first phase of this option exercised by Genesis Digital Assets and is expected to be delivered in the first quarter of 2022.

05:23 EST IBM, AIB enter EUR 65M three-year agreement - AIB, an Irish bank with positions across key segments, and IBM announced a EUR 65M three-year agreement designed to help deliver the bank's 2023 strategy by accelerating its ongoing digital transformation, meeting its commitment and providing a pathway to a hybrid cloud technology environment. Under the agreement, IBM will provide AIB with a next-generation IBM z15 compute platform along with an extensive technology portfolio which includes IBM's Cloud Pak solutions and the capability to deliver services leveraging Red Hat OpenShift. This will help AIB to sustain its high pace of digitalization and its focus on security and resilience.

05:18 EST Roche launches first infectious disease tests on cobas 5800 System - Roche announced the launch of the first infectious disease tests on the cobas 5800 System, a new molecular laboratory instrument, in countries accepting the CE mark. These include cobas HIV-1, cobas HBV, cobas HCV, cobas HIV-1/HIV-2 Qualitative, and the cobas omni Utility Channel kit. These launches expand the Roche Molecular portfolio offering by providing standardized performance and efficiencies across low, medium and high volume molecular laboratory testing needs.

05:12 EST Elbit Systems awarded $350M contract to supply land systems - Elbit Systems announced that it was awarded a contract valued at approximately $350M to supply an array of land systems to an international customer. The contract will be fulfilled over a three-year period.

05:08 EST Ambarella, Autobrains to develop range of ADAS solutions - Ambarella and Autobrains announced a collaboration to develop a scalable range of advanced driver assistance system, or ADAS, solutions for the automotive mass market that will be demonstrated during CES in Las Vegas. Currently, the companies have developed an 8MP front ADAS solution targeting a uniquely compact, single-box form factor. The companies are also working on solutions for the future, including a centralized domain control unit that can utilize multiple cameras and a variety of additional sensors, such as radar, lidar and others.